{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T17:24:29Z","timestamp":1778520269068,"version":"3.51.4"},"reference-count":49,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370208"],"award-info":[{"award-number":["82370208"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82470200"],"award-info":[{"award-number":["82470200"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","pathologyjournal.rcpa.edu.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.pathol.2025.09.013","type":"journal-article","created":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T07:36:42Z","timestamp":1770449802000},"page":"305-319","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["A comprehensive analysis of common cytogenetic abnormalities in multiple myeloma: from basic research to clinical applications"],"prefix":"10.1016","volume":"58","author":[{"given":"Chenbo","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaonan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingbo","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chongli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiao","family":"Shu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gongchang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuisheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miaomiao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pathol.2025.09.013_bib1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41408-022-00679-5","article-title":"High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions","volume":"12","author":"Hagen","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.pathol.2025.09.013_bib2","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3390\/cells10020336","article-title":"Genetic abnormalities in multiple myeloma: prognostic and therapeutic implications","volume":"10","author":"Cardona-Benavides","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.pathol.2025.09.013_bib3","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.92","article-title":"Interpretation of cytogenetic results in multiple myeloma for clinical practice","volume":"5","author":"Rajan","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.pathol.2025.09.013_bib4","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pathol.2025.09.013_bib5","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group","volume":"127","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2025.09.013_bib6","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1200\/JCO.21.02614","article-title":"Second revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY Project","volume":"40","author":"D'Agostino","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pathol.2025.09.013_bib7","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1200\/JCO-24-01893","article-title":"International Myeloma Society\/International Myeloma Working Group\/international myeloma working group consensus recommendations on the definition of high-risk multiple myeloma","volume":"43","author":"Avet-Loiseau","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pathol.2025.09.013_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2024.101168","article-title":"Chromosomal defects in multiple myeloma","volume":"64","author":"Clarke","year":"2024","journal-title":"Blood Rev"},{"key":"10.1016\/j.pathol.2025.09.013_bib9","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41408-025-01286-w","article-title":"Guidelines for the testing and reporting of cytogenetic results for risk stratification of multiple myeloma: a report of the Cancer Genomics Consortium Plasma Cell Neoplasm Working Group","volume":"15","author":"Lu","year":"2025","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.pathol.2025.09.013_bib10","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/ejh.13440","article-title":"IgH translocation with undefined partners is associated with superior outcome in multiple myeloma patients","volume":"105","author":"Mao","year":"2020","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.pathol.2025.09.013_bib11","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/ng0797-260","article-title":"Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3","volume":"16","author":"Chesi","year":"1997","journal-title":"Nat Genet"},{"key":"10.1016\/j.pathol.2025.09.013_bib12","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1535-6108(04)00019-4","article-title":"Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma","volume":"5","author":"Hurt","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pathol.2025.09.013_bib13","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/ajh.27327","article-title":"High-risk multiple myeloma: redefining genetic, clinical, and functional high-risk disease in the era of molecular medicine and immunotherapy","volume":"99","author":"Rees","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.pathol.2025.09.013_bib14","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.pathol.2025.09.013_bib15","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nrclinonc.2016.122","article-title":"Genomic complexity of multiple myeloma and its clinical implications","volume":"14","author":"Manier","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.pathol.2025.09.013_bib16","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2017.12","article-title":"Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker","volume":"7","author":"Chavan","year":"2017","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.pathol.2025.09.013_bib17","article-title":"The significance of RB1 in multiple myeloma","volume":"15","author":"Wang","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.pathol.2025.09.013_bib18","first-page":"1138","article-title":"A diagnostic approach to detect cytogenetic heterogeneity and its prognostic significance in multiple myeloma","volume":"18","author":"Kalal","year":"2023","journal-title":"J Taibah Univ Med Sci"},{"key":"10.1016\/j.pathol.2025.09.013_bib19","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1007\/s00277-014-2057-5","article-title":"Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry study","volume":"93","author":"Oh","year":"2014","journal-title":"Ann Hematol"},{"key":"10.1016\/j.pathol.2025.09.013_bib20","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.127889","article-title":"Rb1\/Rbl1\/Vhl loss induces mouse subretinal angiomatous proliferation and hemangioblastoma","volume":"4","author":"Wei","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.pathol.2025.09.013_bib21","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1093\/nar\/30.8.1859","article-title":"Gene expression changes in response to E2F1 activation","volume":"30","author":"Stanelle","year":"2002","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.pathol.2025.09.013_bib22","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/jcp.24170","article-title":"Emerging roles of RB family: new defense mechanisms against tumor progression","volume":"228","author":"Indovina","year":"2013","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.pathol.2025.09.013_bib23","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1179\/102453309X385250","article-title":"Fluorescent in situ hybridization studies in multiple myeloma","volume":"14","author":"Yuregir","year":"2009","journal-title":"Hematology"},{"key":"10.1016\/j.pathol.2025.09.013_bib24","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1007\/s12032-011-9988-7","article-title":"Fluorescence in situ hybridization analysis of chromosome aberrations in 60 Chinese patients with multiple myeloma","volume":"29","author":"Gao","year":"2012","journal-title":"Med Oncol"},{"key":"10.1016\/j.pathol.2025.09.013_bib25","first-page":"2981","article-title":"Clinical significance of chromosomal abnormalities detected by interphase fluorescence in situ hybridization in newly diagnosed multiple myeloma patients","volume":"124","author":"Hu","year":"2011","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.pathol.2025.09.013_bib26","doi-asserted-by":"crossref","first-page":"15524","DOI":"10.1073\/pnas.242606799","article-title":"Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia","volume":"99","author":"Calin","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pathol.2025.09.013_bib27","doi-asserted-by":"crossref","first-page":"6669","DOI":"10.1182\/blood-2009-01-198408","article-title":"MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma","volume":"113","author":"Roccaro","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2025.09.013_bib28","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41408-021-00474-8","article-title":"Chromosome 1q21 abnormalities in multiple myeloma","volume":"11","author":"Schmidt","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.pathol.2025.09.013_bib29","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1182\/bloodadvances.2020002218","article-title":"Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities","volume":"4","author":"Abdallah","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.pathol.2025.09.013_bib30","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1080\/10428194.2016.1260126","article-title":"Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation","volume":"58","author":"Shah","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.pathol.2025.09.013_bib31","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-019-0254-0","article-title":"Gain of chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone","volume":"9","author":"Schmidt","year":"2019","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.pathol.2025.09.013_bib32","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1006\/geno.1994.1523","article-title":"Human and mouse chromosomal mapping of the myeloid cell leukemia-1 gene: MCL1 maps to human chromosome 1q21, a region that is frequently altered in preneoplastic and neoplastic disease","volume":"23","author":"Craig","year":"1994","journal-title":"Genomics"},{"key":"10.1016\/j.pathol.2025.09.013_bib33","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/sj.leu.2403784","article-title":"Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival","volume":"19","author":"Wuill\u00e8ME-Toumi","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2025.09.013_bib34","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","article-title":"A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1","volume":"109","author":"Shaughnessy","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2025.09.013_bib35","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1182\/blood.2023023487","article-title":"TP53 function over forms in multiple myeloma","volume":"143","author":"Neri","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2025.09.013_bib36","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/717919","article-title":"p53 abnormalities and potential therapeutic targeting in multiple myeloma","volume":"2014","author":"Teoh","year":"2014","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.pathol.2025.09.013_bib37","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1309\/AJCPHC85DGAXZDBE","article-title":"p53 nuclear expression correlates with hemizygous TP53 deletion and predicts an adverse outcome for patients with relapsed\/refractory multiple myeloma treated with lenalidomide","volume":"137","author":"Chen","year":"2012","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.pathol.2025.09.013_bib38","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/leu.2013.225","article-title":"Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients","volume":"28","author":"Hebraud","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.pathol.2025.09.013_bib39","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s11684-019-0712-x","article-title":"Clinical characteristics and prognostic values of 1p32.3 deletion detected through fluorescence in situ hybridization in patients with newly diagnosed multiple myeloma: a single-center study in China","volume":"14","author":"Wang","year":"2020","journal-title":"Front Med"},{"key":"10.1016\/j.pathol.2025.09.013_bib40","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.7754\/Clin.Lab.2013.130743","article-title":"Effect of 13q deletion on IL-6 production in patients with multiple myeloma: a hypothesis may hold true","volume":"60","author":"Neemat","year":"2014","journal-title":"Clin Lab"},{"key":"10.1016\/j.pathol.2025.09.013_bib41","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3390\/cancers13020256","article-title":"Gain\/amplification of chromosome arm 1q21 in multiple myeloma","volume":"13","author":"Hanamura","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.pathol.2025.09.013_bib42","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/ejh.12546","article-title":"Proteasome inhibitors and IMiDs can overcome some high-risk cytogenetics in multiple myeloma but not gain 1q21","volume":"96","author":"Nahi","year":"2016","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.pathol.2025.09.013_bib43","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1182\/blood-2012-02-408922","article-title":"Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA\/GEM study","volume":"120","author":"Rosi\u00f1OL","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.pathol.2025.09.013_bib44","article-title":"Chromosome 1q21 gain is an adverse prognostic factor for newly diagnosed multiple myeloma patients treated with bortezomib-based regimens","volume":"12","author":"Liu","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.pathol.2025.09.013_bib45","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00277-021-04704-8","article-title":"Outcomes of patients with multiple myeloma harboring chromosome 1q gain\/amplification in the era of modern therapy","volume":"101","author":"Hu","year":"2022","journal-title":"Ann Hematol"},{"key":"10.1016\/j.pathol.2025.09.013_bib46","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1080\/10428194.2019.1700503","article-title":"1q21 gain but not t(4;14) indicates inferior outcomes in multiple myeloma treated with bortezomib","volume":"61","author":"Du","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.pathol.2025.09.013_bib47","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00428-019-02725-3","article-title":"A review on tumor heterogeneity and evolution in multiple myeloma: pathological, radiological, molecular genetics, and clinical integration","volume":"476","author":"Sch\u00fcRCH","year":"2020","journal-title":"Virchows Arch"},{"key":"10.1016\/j.pathol.2025.09.013_bib48","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41467-017-00296-y","article-title":"Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing","volume":"8","author":"Rasche","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.pathol.2025.09.013_bib49","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1182\/blood-2015-12-686782","article-title":"Spatially divergent clonal evolution in multiple myeloma: overcoming resistance to BRAF inhibition","volume":"127","author":"Raab","year":"2016","journal-title":"Blood"}],"container-title":["Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302526003867?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302526003867?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T21:26:37Z","timestamp":1774041997000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031302526003867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0031302526003867"],"URL":"https:\/\/doi.org\/10.1016\/j.pathol.2025.09.013","relation":{},"ISSN":["0031-3025"],"issn-type":[{"value":"0031-3025","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A comprehensive analysis of common cytogenetic abnormalities in multiple myeloma: from basic research to clinical applications","name":"articletitle","label":"Article Title"},{"value":"Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pathol.2025.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}